// Contents

“I was 46. It was now or never.” That is how a Dutch woman named Wendy explained to reporters why she paid more than $30,000 for a procedure that is off-limits in the United States. She flew out for three egg retrievals: twice to Tirana, the capital of Albania, and once to a partner clinic in Georgia, the former Soviet republic. Her eggs produced 11 embryos rebuilt with a stranger’s mitochondria. Two of them developed far enough to be transferred. One turned out to have a chromosome error; the other went into her womb. The pregnancy test came back negative.

Wendy, who gave only her first name, is one of the women in a STAT investigation published on November 2, 2026. Over eight months, its reporters traced how a technique built to stop rare inherited diseases became “egg rejuvenation” for women over 40. The most awkward detail for the sellers comes from experiments by Ukrainian embryologist Pavlo Mazur. When he moved the nuclei of patients aged 36 to 44 into young donor eggs, only one woman out of 19 got an embryo with the correct number of chromosomes. When he did the opposite and put young nuclei into the patients’ own eggs, 70% of the embryos that made it to transfer had normal chromosomes. The mitochondria in the aging eggs had been working fine all along. What breaks is the chromosomes, and new mitochondria can’t fix those.

A baby with three parents

Mitochondria are tiny structures that power the cell. They carry their own DNA, and a child inherits it from the mother alone. If that DNA is faulty, the child can be born with a severe disease of the muscles, heart or brain.

Mitochondrial replacement was invented to get around that fault. Put simply, the egg gets new “batteries.” Doctors lift out the nucleus, which holds the mother’s DNA and almost everything the child will inherit. They place it in a donor egg that has lost its own nucleus but kept its healthy mitochondria. The swap happens either just before fertilization or just after. The child ends up with the genes of its mother and father plus a small share of the donor’s DNA. Hence the tabloid name, “three-parent IVF.”

For its original purpose, the method works. In July 2025, doctors in Newcastle, England, reported eight children born after this kind of transfer to seven women at high risk of passing on a mitochondrial disease. None of the children shows signs of the disease. In the UK, only one clinic is allowed to do it, and the regulator approves each case individually. In the US, the method has been effectively banned since 2015: a rider in a spending bill stops the FDA, the US drug regulator, from even accepting an application for a trial that modifies a human embryo.

From a rare-disease fix to a fertility tour package

The US ban hasn’t stopped American women. International Fertility Group of North America (IFG), a company based outside Chicago, describes itself as a medical tourism facilitator: it doesn’t treat anyone itself but refers patients to clinics abroad, most often the SAGA Clinic in Tirana. According to STAT, the SAGA lobby displays a sign with the FDA logo. All it means is that the clinic appears in the FDA’s database of registered establishments. It is not a license, and it is not an approval.

The IFG package cost $20,000: mitochondrial transfer for up to 15 embryos, plus the first egg retrieval. In 2026 the price rose to $30,000, with medications, donor eggs and genetic testing billed separately. For $1,000, clients could jump ahead on the waitlist. On social media, the company listed the procedure among “12 miracles” and promised it would “boost egg energy” with healthy mitochondria.

// The mitochondria business

$30,000price of the IFG package in 2026, before medications and donor eggs
45.6 yearsaverage age of IFG clients, per a slide from a company webinar; in 2022 it was 39.2
34babies born through the program, according to IFG itself as of February 2025
up to 200births after such transfers worldwide, by the estimate of fertility industry insiders; nobody keeps an exact count

The client ages say more than the ads do. The method was designed for young women with faulty mitochondria, yet the buyers are women in their mid-forties whose eggs have simply aged. Nobody knows how many women have traveled for the procedure. STAT puts the number in the hundreds.

Women fly abroad for mitochondrial transfer
Women fly abroad for mitochondrial transfer

The batteries were never the problem

The sales pitch sounds logical. Eggs age, their mitochondria wear out, so swapping the “batteries” should make them young again. Pavlo Mazur, one of the pioneers of transferring the nucleus after fertilization, did exactly what IFG sells. He moved each patient’s nucleus into a young donor egg with fresh mitochondria. He tried it with 19 women aged 36 to 44. Only one of them, a 42-year-old, ever got an embryo with the correct number of chromosomes.

So Mazur ran the experiment backward. He took the nuclei from young donors’ eggs and placed them into the older patients’ eggs, which still held their own “old” mitochondria. Of the embryos made this way, 40% grew to the stage where they could be transferred, and 70% of those had normal chromosomes. The older women’s mitochondria were fine. The nucleus had been the problem all along.

In battery terms: fresh batteries did nothing for the old machinery, while new machinery ran fine on the old batteries.

That fits what has long been known about age and IVF. The main trouble with an aging egg is aneuploidy, an embryo with the wrong number of chromosomes. Such an embryo usually fails to implant, or the pregnancy ends early. The rate of these errors climbs steadily through a woman’s thirties and spikes after 40. Mitochondrial transfer carries that same nucleus, errors and all, into the donor egg.

“It’s too late to make a difference,” Mazur told reporters, speaking of older women’s eggs. He hasn’t published his data yet, so this is one lab’s observation rather than a peer-reviewed result. Then again, there is no peer-reviewed evidence for the sellers’ claim at all.

The reverse experiment: a young nucleus in an older egg
The reverse experiment: a young nucleus in an older egg

What made it into the journals

The reporters found only one peer-reviewed study of mitochondrial transfer for infertility. It came out in 2023 in Fertility and Sterility and followed 25 couples at a Greek clinic who had been through several failed rounds of IVF. Every woman in it was under 40. Six children were born. The authors themselves wrote that it was too early to claim the method works. STAT found an age breakdown in the paper’s supplement: for the 12 participants who were 39, the live birth rate fell below 10%.

The same paper contains a detail the ads leave out. In one of the six children, the share of the mother’s own mitochondria rose to 30–60% by birth, even though there had been almost none at the embryo stage. In other words, the new “batteries” may not stick, and patients pay for the procedure without knowing what will end up in their child’s cells.

Better numbers appear in a 2025 paper in The Journal of Reproduction: a 48.3% live birth rate in 27 older patients. STAT pointed out several problems. The paper was accepted less than three weeks after submission. Uliana Dorofeyeva, IFG’s advisory clinical director, sat on the journal’s editorial board, and an ad for a company linked to her ran alongside the paper. And the journal isn’t indexed in major scientific databases.

The yardstick for any “rejuvenation” already exists. In the largest single-clinic cohort, which covered 1,078 cycles of standard IVF in women 45 and older using their own eggs, only 3.4% of transfers led to a birth.

// Promises and data

What the ads said

Mitochondrial transfer “boosts egg energy,” and pregnancy follows in more than 50% of cycles (IFG later specified 54%).

What the research shows

There is no peer-reviewed data on women over 40. Standard IVF at 45 and older ends in a birth in 3.4% of transfers, and no peer-reviewed study shows that mitochondrial transfer does better.

Aimee Eyvazzadeh, a fertility specialist in the San Francisco Bay Area, referred about 50 older patients over three years to IFG and two other clinics that perform the transfer. “Unfortunately, I have not had a success story yet,” she told STAT.

“The science is not magic”

Shoukhrat Mitalipov of Oregon Health & Science University, who developed the before-fertilization version of the swap, doubts the method will help women over 40, though he notes that he hasn’t tested it himself.

Birol Aydin, the embryologist who performed the procedures in Tirana, said he turned away about 80% of applicants. “Of course, the science is not magic,” he added. He has since stepped back for health reasons and, in his words, no longer believes patients should pay for an experimental treatment.

Once reporters started asking questions, IFG paused enrollment, told clients the last group would be treated in October, and then scrubbed every mention of mitochondrial transfer from its website. The company called this “a precautionary communications decision,” not an admission that its earlier statements were inaccurate. It has not shared its patient data with scientists. So the central question remains open: how many women gave birth after the procedure, and how many would have without it?

The investigation boils down to three questions to put to any clinic that promises to rejuvenate eggs. Are its results published in a peer-reviewed journal? Did its studies include women the same age as the patient? What number does it compare its results against? For women 45 and older, the honest one is 3.4% births per transfer with standard IVF.

Jeffrey Kahn, who directs the Berman Institute of Bioethics at Johns Hopkins University, summed up the deal in one line: “You’re paying for the privilege of being a guinea pig.”